Android app on Google Play

Keryx Biopharma (KERX) Pulls-Back After Ripping Over 160% on Zerenex DAta

February 1, 2013 11:54 AM EST Send to a Friend
Looks like the ride for Keryx Biopharmaceuticals Inc. (KERX) might be coming to a close.

After moving up 165 percent this week through Thursday, shares of Keryx are retracing a bit today. The stock is down over 15 percent on volume as traders look to cash out on some profits.

The move started Monday when Keryx announced Zerenex met its primary endpoint and secondary endpoint in Phase 3 trials.

Short interest through January 15th is 11.02 million shares, or 15.7 percent of float.




You May Also Be Interested In


Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment